**Saudi Journal of Medicine and Public Health**

https://saudijmph.com/index.php/pub

https://doi.org/10.64483/202522438

# Portal Hypertension: Integrated Internal Medicine Management with Laboratory Evaluation, Radiologic Assessment, and Family Medicine–Based Longitudinal Care

**Moneef Mansour Aldosari [(1)] , Ghada Zaal Alrowaili [(2)] , Othman Mohammed Almousa [(3)] , Abada Awaji Hakami [(4)] , Essa Hassan Essa Abu Alzwaid [(5)] , Amin Ibrahim Ahmed Otaif [(6)] , Amal Ali Soliman Gahtani [(7)] , Hussen Bahws Saeed Alhsnani [(8)] , Mohd Husain Mobarki [(9)] , Salem Ali Aldhafeeri [(10)] , Salman Mkazi Sulaiman Alshammri [(11)]**

*(1) Al Sulayl General Hospital,Ministry of Health, Saudi Arabia,*
*(2) Aljouf Health Cluster ,Saudi Board Of Family Medicine,Ministry of Health, Saudi Arabia,*
*(3) Badr Health Center 3 First Health Cluster At The Ministry Of Health, Saudi Arabia,*
*(4) South Quantha Hospital,Ministry of Health, Saudi Arabia,*
*(5) King Fahd Hospital,Ministry of Health, Saudi Arabia,*
*(6) Ma'taq Al-Asm Health Center,Ministry of Health, Saudi Arabia,*
*(7) Ministry Of Health ,Jazan, Saudi Arabia,*
*(8) Al-Laith General Hospital,Ministry of Health, Saudi Arabia,*
*(9) Ahad Almasariha General Hospital,Ministry of Health, Saudi Arabia,*
*(10) King Khaled General Hospital Hafer Albatin,Ministry of Health, Saudi Arabia,*
*(11) King Khalid General Hafr Albatin,Ministry of Health, Saudi Arabia*

## Abstract

**Background:** Portal hypertension is a major hemodynamic consequence of chronic liver disease and other hepatic or extrahepatic disorders. It drives complications such as variceal bleeding, ascites, and encephalopathy, significantly impacting morbidity and mortality.

**Aim:** To provide an integrated review of portal hypertension, emphasizing pathophysiology, diagnostic strategies, and multidisciplinary management.

**Methods:** A comprehensive synthesis of current evidence and guidelines was performed, covering hemodynamic principles, etiologic classification, laboratory and imaging evaluation, and therapeutic approaches including pharmacologic, endoscopic, and interventional strategies.

**Results:** Portal hypertension arises from increased intrahepatic resistance and augmented splanchnic inflow, leading to collateral formation and systemic circulatory changes. Clinically significant portal hypertension (HVPG ≥10 mm Hg) predicts decompensation, while ≥12 mm Hg correlates with variceal bleeding risk. Noninvasive tools such as elastography and Doppler ultrasound complement invasive HVPG measurement. Management integrates etiologic therapy, nonselective beta-blockers (preferably carvedilol), endoscopic prophylaxis, and escalation to TIPS or transplantation for refractory complications. Preventive strategies—alcohol abstinence, metabolic optimization, and early antiviral therapy—remain pivotal.

**Conclusion:** Portal hypertension is a multifactorial syndrome requiring early detection, risk stratification, and coordinated care across specialties. Evidence-based interventions targeting both underlying disease and portal pressure reduction improve survival and quality of life.

**Keywords:** Portal hypertension, hepatic venous pressure gradient, cirrhosis, variceal bleeding, nonselective beta-blockers, TIPS, elastography.

## Introduction

Portal hypertension denotes an abnormal elevation of pressure within the portal venous circulation and represents a central hemodynamic consequence of a wide range of hepatic and extrahepatic disorders. The term “portal hypertension” was introduced by Gilbert and Carnot in 1902 to describe the clinical constellation of findings and complications attributable to increased pressure within the liver’s venous outflow system. Conceptually, portal hypertension is best defined not merely by an absolute portal pressure value—which is difficult to measure directly in routine clinical practice—but by an increased portal pressure gradient. This gradient reflects the pressure difference between the portal venous system and the systemic venous circulation, typically referenced to the inferior vena cava or hepatic venous pressure, thereby providing a clinically useful index of the driving force that promotes collateral formation and


*Corresponding author e-mail: Dr-Moneef@Hotmail.Com (Moneef Mansour Aldosari).
Receive Date: 01 December 2025, Revise Date: 28 December 2025, Accept Date: 31 December 2025

decompensating sequelae. In contemporary hepatology, the hepatic venous pressure gradient (HVPG) serves as the standard surrogate measure of portal pressure. Physiologically, an HVPG of ≤5 mm Hg is considered normal. Values ≥6 mm Hg are consistent with portal hypertension, whereas a gradient in the 5–9 mm Hg range is often interpreted as subclinical disease, reflecting early hemodynamic derangement that may precede overt complications.[1] Importantly, the clinical relevance of portal hypertension is strongly threshold-dependent. The onset of clinically significant portal hypertension (CSPH) is generally recognized at an HVPG of 10 mm Hg or greater, a level at which the risk of clinically meaningful events—including variceal development and progression to decompensation—substantially increases.[1] As the gradient rises further, the probability of major decompensating events escalates; in particular, complications such as ascites, hepatic encephalopathy, and gastrointestinal bleeding are most commonly observed when HVPG reaches ≥12 mm Hg, underscoring the close relationship between portal hemodynamics and adverse clinical outcomes [1][2].

The pathogenesis of portal hypertension is fundamentally driven by increased resistance to portal blood flow, frequently compounded by dynamic changes in splanchnic circulation. In many patients, resistance develops within the liver itself, most commonly as a consequence of cirrhosis, where architectural distortion, fibrotic remodeling, regenerative nodularity, and sinusoidal endothelial dysfunction collectively impede portal perfusion. However, elevated portal pressure can also arise in the absence of cirrhosis. In these noncirrhotic contexts, the critical determinant remains the anatomic site of resistance, which may occur before, within, or after the hepatic sinusoids. This framework supports a clinically meaningful classification into prehepatic, intrahepatic, and posthepatic causes, each associated with distinct diagnostic patterns and management implications. Prehepatic etiologies include conditions such as portal vein thrombosis, in which obstruction proximal to the liver increases upstream pressure. Posthepatic causes include disorders that impair hepatic venous outflow or right-sided cardiac filling, such as Budd–Chiari syndrome or constrictive pericarditis, where resistance is imposed after blood has traversed the hepatic microcirculation. The broader category of noncirrhotic portal hypertension (NCPH) encompasses these prehepatic and posthepatic disorders as well as selected intrahepatic processes that elevate portal resistance without the classic histologic features of cirrhosis. Recognizing NCPH is clinically important because patients may present with portal hypertensive complications despite relatively preserved synthetic liver function, and management priorities may differ from those of cirrhosis-related portal hypertension. Consequently, localizing the level of resistance—through integrated clinical assessment, laboratory evaluation, and imaging—serves as a foundational step in identifying the underlying disease mechanism, estimating risk, and selecting appropriate therapy. Among individuals with cirrhosis, portal hypertension is not a secondary or incidental finding; rather, it is a principal driver of morbidity and a dominant predictor of hospitalization, transplant evaluation, and mortality. The clinical course of chronic liver disease is often defined by the transition from compensated cirrhosis to decompensated cirrhosis, a transition that is frequently mediated by progressive portal pressure elevation and the emergence of complications such as variceal hemorrhage, ascites, and encephalopathy. For this reason, portal hypertension functions as both a mechanistic cornerstone in the pathophysiology of advanced liver disease and a practical clinical construct that guides surveillance, risk stratification, and preventive intervention across internal medicine, hepatology, radiology, and longitudinal family medicine care.[1]

**Etiology**

Portal hypertension arises when portal venous inflow exceeds the capacity of the portal system to drain into the systemic circulation, most commonly because resistance to blood flow increases somewhere along the portal venous pathway. Etiologic classification is traditionally organized by the anatomical site of the primary obstruction or resistance—prehepatic, intrahepatic, or posthepatic—because this localization provides a practical diagnostic framework and helps anticipate associated clinical features, laboratory patterns, and imaging findings. Although cirrhosis is the most frequent cause worldwide, a substantial subset of patients develop portal hypertension through noncirrhotic mechanisms, and accurate etiologic attribution is critical because treatment priorities and prognostic implications may differ. Prehepatic portal hypertension reflects resistance or obstruction occurring before portal blood enters the hepatic sinusoids. In this category, the portal venous inflow may be increased, or the portal/splenic venous channels may be mechanically narrowed or occluded. Increased portal inflow is less common but may occur in conditions that augment splanchnic blood flow, such as arteriovenous malformations or arteriovenous fistulas. In certain endemic settings, idiopathic tropical splenomegaly has been associated with marked splenic enlargement and altered splanchnic hemodynamics that can contribute to increased portal inflow.[1] More frequently, prehepatic portal hypertension results from obstruction of the portal vein or splenic vein. Portal vein thrombosis is a prototypical cause and may arise in association with local inflammatory processes,

malignancy, hypercoagulable states, or cirrhosis; however, it can also occur without advanced liver disease and may present with variceal bleeding despite preserved hepatic synthetic function. Obstruction can also develop from tumor invasion, external compression by adjacent masses or lymphadenopathy, or fixed structural abnormalities such as portal vein stenosis.[1] The clinical hallmark of purely prehepatic disease is that portal hypertensive complications (e.g., varices and splenomegaly) may occur while intrinsic hepatocellular function remains relatively intact, a pattern that should prompt clinicians to consider extrahepatic obstruction early in the diagnostic workup [1][2].




**Fig. 1:** Etiology of Portal hypertension.

**Intrahepatic etiologies**

Intrahepatic causes are subdivided into presinusoidal, sinusoidal, and postsinusoidal categories, reflecting the anatomic level within the hepatic microcirculation at which resistance predominates. Presinusoidal causes elevating portal pressure before blood traverses the sinusoidal network. Classic presinusoidal etiologies include schistosomiasis, where periportal fibrosis increases resistance without necessarily producing cirrhosis, and congenital hepatic fibrosis, which can lead to portal hypertension early in life. Granulomatous and cholestatic disorders such as sarcoidosis and early primary biliary cholangitis may also produce presinusoidal resistance, as can chronic active hepatitis and certain toxic exposures.[1] Industrial and environmental toxins—including vinyl chloride, arsenic, and copper—have been implicated in vascular and periportal injury patterns that may manifest with portal hypertension even when overt cirrhosis is absent.[1] Sinusoidal portal hypertension is the most common intrahepatic form and is most closely associated with cirrhosis. In cirrhosis, fibrotic remodeling, regenerative nodules, and sinusoidal endothelial dysfunction collectively distort hepatic architecture and create fixed and dynamic increases in resistance. Alcohol-related hepatitis can also contribute to sinusoidal resistance through inflammatory swelling and microvascular dysfunction, and other contributors include vitamin A intoxication and cytotoxic drugs, which may induce sinusoidal injury and fibrosis.[1] Advanced primary biliary cholangitis, once architectural distortion becomes pronounced, may likewise behave as a sinusoidal cause. Postsinusoidal intrahepatic portal hypertension is classically associated with sinusoidal obstruction syndrome (SOS), also known as veno-occlusive disease (VOD), in which injury to the terminal hepatic venules and adjacent sinusoids impedes outflow within the liver, producing portal pressure elevation and potentially rapid decompensation.[1]

**Posthepatic etiologies**

Posthepatic portal hypertension results from impaired venous drainage after blood has traversed the hepatic sinusoids, typically at the level of the hepatic veins, inferior vena cava, or the right heart. Budd–Chiari syndrome—hepatic venous outflow obstruction due to thrombosis or compression—is a major posthepatic etiology and can present acutely with painful hepatomegaly and ascites or more chronically with portal hypertensive complications. At the cardiac level, any disorder that increases right atrial pressure can transmit backpressure to the hepatic venous system, reducing the gradient for hepatic outflow. Constrictive pericarditis, tricuspid insufficiency, and restrictive cardiomyopathy are important cardiac causes that should be considered when portal hypertension coexists with signs of right-sided heart failure.[1] Lesions of the inferior vena cava—including stenosis, thrombosis, congenital webs, or tumor invasion—can similarly obstruct venous return and generate a posthepatic portal hypertensive state. In such cases, the clinical profile may include hepatomegaly, ascites, and peripheral edema, and the management strategy often requires addressing the underlying cardiac or caval pathology in addition to treating portal hypertensive complications.

**Idiopathic portal hypertension**

Idiopathic portal hypertension describes a syndrome of elevated portal pressure in the absence of histologic cirrhosis and without extrahepatic portal vein obstruction. It has been reported more commonly in Japan and India and is characterized by portal hypertensive manifestations—often marked splenomegaly and variceal bleeding—despite relatively preserved liver function tests and minimal ascites.[1] The etiology remains incompletely understood, but proposed contributors include recurrent septic embolization from the gastrointestinal tract, HIV infection, and prior chemotherapy exposure, particularly regimens including oxaliplatin.[1] Clinically, idiopathic portal hypertension is important because it challenges the assumption that clinically significant portal hypertension necessarily implies cirrhosis, and it underscores the need for careful radiologic and laboratory evaluation to define the site and mechanism of resistance before prognostication or long-term management decisions are made.

**Epidemiology**

The epidemiology of portal hypertension closely mirrors the global distribution of its underlying etiologies, particularly chronic liver disease and region-specific infectious causes. In high-income settings and much of the Western world, cirrhosis remains the dominant driver of portal hypertension, reflecting the prevalence of chronic hepatocellular injury from alcohol-associated liver disease, chronic viral hepatitis, and the growing burden of metabolic dysfunction–associated steatotic liver disease (MASLD) and its progressive forms. As a consequence, portal hypertension in these regions is most commonly encountered as a complication of advanced hepatic fibrosis and architectural distortion, and it frequently defines the clinical transition from compensated to decompensated cirrhosis through events such as ascites, variceal hemorrhage, and hepatic encephalopathy. Accordingly, the overall population-level burden of portal hypertension in these settings is strongly influenced by the incidence of cirrhosis and by healthcare system capacity for early detection, risk-factor modification, and timely referral for hepatology care. In contrast, the epidemiologic landscape differs substantially in many low- and middle-income countries, where infectious and environmental exposures contribute disproportionately to portal hypertensive disease. Schistosomiasis is a particularly important determinant in endemic regions of Africa, where it represents the most frequent cause of portal hypertension.[1] In hepatosplenic schistosomiasis, chronic parasitic infection can induce periportal fibrosis and presinusoidal obstruction, producing clinically significant portal hypertension even when hepatocellular synthetic function is relatively preserved. This distinction has major clinical implications: patients may present with pronounced splenomegaly and variceal bleeding without the typical biochemical profile of cirrhotic liver failure, and the public health approach must incorporate parasite control, sanitation strategies, and targeted treatment programs to reduce incidence and severity [1][2][3].

From a global mortality perspective, cirrhosis contributes substantially to deaths attributable to end-stage liver disease and its complications, including portal hypertension. In 2017, approximately 2.4% of all deaths worldwide were attributed to cirrhosis, corresponding to roughly 1.32 million deaths.[2] These figures highlight the scale of advanced liver disease as a worldwide health problem and, by extension, the substantial downstream burden of portal hypertension as a mechanistic and clinical consequence of cirrhosis. Importantly, the epidemiology of portal hypertension cannot be fully captured by prevalence estimates alone; it is also reflected in healthcare utilization patterns, including recurrent hospitalization for decompensation, need for endoscopic surveillance and therapy, and liver transplantation demand in eligible populations. Thus, portal hypertension represents both a clinical syndrome and a population health indicator—one that varies by geography, socioeconomic context, and dominant etiologic exposures.[1][2]

**Pathophysiology**

Portal hypertension is fundamentally a disorder of altered hepatic and splanchnic hemodynamics in which resistance to portal venous inflow increases and, in many cases, portal venous inflow itself becomes pathologically augmented. Understanding this condition requires an appreciation of normal portal circulation, the determinants of vascular resistance within and around the liver, and the systemic neurohumoral responses that evolve as the disease progresses. The liver receives a dual blood supply from the hepatic artery and the portal vein, with the portal vein providing the majority of hepatic inflow. The portal vein is formed by the confluence of the superior mesenteric vein and the splenic vein and typically measures approximately 7 to 8 cm in length. It drains blood from the spleen, pancreas, and gallbladder, as well as venous return from the esophagus, stomach, and the large and small intestines. After entering the hepatic hilum, the portal vein divides into right and left portal branches that distribute blood to the corresponding lobes of the liver. Portal venous blood then traverses the hepatic sinusoids—specialized low-pressure vascular channels that facilitate exchange between blood and hepatocytes—before draining into the central veins, then into the hepatic veins, and ultimately into the inferior vena cava and systemic circulation. Physiologically, portal venous pressure is slightly higher than hepatic venous pressure, creating a gradient that drives blood through the sinusoidal network and into the systemic venous system. The portal vein pressure is typically in the range of 1 to 4 mm Hg higher than hepatic venous pressure, and the portal venous system, like most venous channels, lacks valves. This valve-free architecture is clinically relevant because it permits bidirectional flow under abnormal pressure conditions and enables the development of portosystemic collateral pathways when portal resistance rises. When resistance anywhere along the portal venous tract increases, upstream portal pressure elevates, establishing the hemodynamic basis of portal hypertension. Depending on the location of the resistance, portal hypertension may be prehepatic (e.g., portal vein thrombosis), intrahepatic (most commonly cirrhosis), or posthepatic (e.g., hepatic venous outflow obstruction) [1][2][3].

**Increased intrahepatic resistance: structural and dynamic components**

In most patients, particularly in the Western world, the predominant site of increased resistance is

intrahepatic. In cirrhosis, resistance is elevated through both fixed structural changes and dynamic, potentially modifiable vascular tone abnormalities. The structural component reflects remodeling of the hepatic microcirculation: chronic injury triggers activation of hepatic stellate cells, which transform into myofibroblast-like cells that deposit extracellular matrix and drive fibrosis. With time, fibrous septa and regenerative nodules distort sinusoidal architecture, compress vascular channels, and create areas of vascular occlusion and aberrant angiogenesis. These changes narrow the effective lumen through which portal blood must flow, increasing resistance in a manner analogous to a chronic "microvascular stenosis" distributed throughout the liver. The dynamic component of intrahepatic resistance arises from dysregulation of liver sinusoidal endothelial cells and activated stellate cells, producing a net increase in vasoconstrictor tone.[3] In the normal liver, sinusoidal endothelial cells help maintain low-resistance flow by producing vasodilators such as nitric oxide. In cirrhosis, endothelial dysfunction reduces nitric oxide bioavailability, while production of vasoconstrictors such as endothelin increases. The combined effect is sinusoidal constriction and increased hepatic vascular resistance, even beyond what would be expected from fibrosis alone. This dynamic element is clinically important because it explains why portal pressure can fluctuate and why pharmacologic therapies that reduce intrahepatic tone or decrease portal inflow can meaningfully lower portal pressure despite persistent structural disease [3].

**Splanchnic vasodilation and increased portal inflow**

Portal hypertension is not solely a problem of increased resistance; it is also perpetuated by increased portal venous inflow driven by splanchnic arterial vasodilation. As intrahepatic resistance rises and portal pressure increases, the body develops a hyperdynamic circulatory state characterized by decreased systemic vascular resistance, increased cardiac output, and expanded splanchnic blood flow. The central mediator of this process is enhanced production of vasodilators in the splanchnic circulation, particularly nitric oxide, which is upregulated in response to increased shear stress and inflammatory signaling. In addition, effective arterial blood volume declines because vasodilation increases vascular capacitance, leading to relative underfilling of the arterial circulation despite normal or increased total body fluid. This perceived underfilling drives further neurohumoral activation and vasodilator release, amplifying splanchnic vasodilation and increasing blood flow through the mesenteric arteries. The consequence is a higher volume of blood delivered into the portal venous system, which further elevates portal pressure in the setting of already increased hepatic resistance. Thus, portal hypertension evolves through a reinforcing loop: intrahepatic resistance rises, portal pressure increases, splanchnic vasodilation augments portal inflow, and the heightened inflow further increases portal pressure and worsens the hemodynamic derangement.[4]




**Fig. 2:** Pathogenesis of portal hypertension.

**Development of portosystemic collaterals and flow reversal**

Persistent elevation in portal pressure triggers the formation and enlargement of portosystemic collateral vessels, a compensatory mechanism aimed at decompressing the high-pressure portal system by diverting blood into lower-pressure systemic venous pathways.[5] Under normal conditions, these collateral channels exist as small, functionally inconsequential connections that carry minimal blood and generally direct flow toward the portal vein. With portal hypertension, the pressure gradient reverses and blood preferentially flows away from the portal circulation toward systemic veins. This reversal is enabled by the absence of venous valves and by progressive dilation of collateral channels under sustained pressure. Collateral formation tends to become clinically important at several characteristic anatomic sites. The distal esophagus and proximal stomach are major regions where left gastric (coronary) venous drainage connects to systemic veins, leading to gastroesophageal varices. Around the umbilicus, recanalization of embryologic venous pathways can occur via connections between the left portal vein and the umbilical vein, producing abdominal wall collaterals. Retroperitoneal collateralization may involve connections between portal tributaries and systemic veins such as iliac and gonadal (ovarian) veins. In the anorectal region, venous connections between portal drainage (superior rectal vein) and systemic drainage (middle and inferior rectal veins) can enlarge, producing rectal varices. These collateral pathways are adaptive in the sense that they reduce portal pressure, but they are also hazardous because thin-walled varices exposed to high flow and pressure can rupture, causing life-threatening hemorrhage [2][3][4][5].

**Systemic consequences**

As portal hypertension progresses and the splanchnic circulation dilates, effective arterial blood volume falls despite total body fluid expansion. The body interprets this as a threat to perfusion and responds through neurohumoral activation, most prominently the renin–angiotensin–aldosterone system (RAAS). Activation of RAAS increases sodium and water retention, expanding plasma volume and contributing to edema and ascites formation.[6] In parallel, sympathetic nervous system activation and non-osmotic release of antidiuretic hormone may occur, further promoting renal vasoconstriction, water retention, and impaired free water excretion. These responses are initially compensatory, aimed at maintaining arterial pressure, but they become maladaptive in cirrhosis and portal hypertension, fueling fluid overload, worsening ascites, and increasing the risk of hyponatremia and hepatorenal physiology [6].

**Hemostatic imbalance, thrombosis, and vascular complications**

Portal hypertension historically was framed within a simplistic model of cirrhosis as a predominantly "bleeding" condition. Contemporary understanding recognizes a far more complex hemostatic balance in which both pro-hemorrhagic and prothrombotic tendencies coexist.[7] Reduced synthesis of clotting factors can increase bleeding risk, particularly in the setting of varices and portal hypertensive gastropathy, yet concomitant reductions in natural anticoagulants and changes in platelet function and endothelial biology can promote thrombosis. This rebalanced but fragile hemostatic state helps explain why patients with cirrhosis may experience portal vein thrombosis and other thrombotic events even while having abnormal conventional coagulation tests. The prothrombotic environment may also accelerate hepatic fibrosis by promoting microthrombi formation in the hepatic microcirculation, thereby worsening ischemia and stimulating fibrogenic pathways. Additionally, portal hypertension and cirrhosis can contribute to pulmonary vascular complications, including pulmonary hypertension, through complex mechanisms involving vasoactive mediators and altered blood flow.[8] A critical modern insight into portal hypertension pathophysiology is the role of the gut–liver axis and bacterial translocation. In cirrhosis, movement of bacteria or bacterial products from the gut lumen into mesenteric lymph nodes and systemic circulation occurs with increased frequency, likely facilitated by altered intestinal permeability, changes in gut microbiota, impaired immune defenses, and increased portal pressure.[9] These microbial products stimulate hepatic stellate cells and Kupffer cells (resident hepatic macrophages), activating inflammatory cascades that promote fibrogenesis and angiogenesis.[10] The resulting increase in fibrosis and aberrant vascular remodeling further elevates intrahepatic resistance and strengthens the pathologic cycle of portal hypertension. Moreover, inflammatory mediators generated in response to bacterial translocation can contribute to systemic vasodilation and worsening hyperdynamic circulation, further increasing splanchnic inflow and portal pressure. In this manner, bacterial translocation functions not merely as a complication of cirrhosis but as an active driver of disease progression and portal hypertensive severity. Portal hypertension emerges from the convergence of increased resistance to portal venous flow—most commonly within the liver due to structural distortion and dynamic vasoconstriction—and increased portal inflow driven by splanchnic vasodilation.[3][4] Sustained pressure elevation promotes portosystemic collateral formation with flow reversal, which decompresses the portal system but creates high-risk varices prone to bleeding.[5] The resulting hyperdynamic circulation and reduced effective arterial volume activate RAAS and other neurohumoral systems, promoting sodium and water retention and contributing to ascites and related complications.[6] Superimposed on these hemodynamic alterations is a complex hemostatic rebalancing with prothrombotic potential that may exacerbate fibrosis and vascular complications,[7][8] while bacterial translocation through the gut–liver axis stimulates fibrogenesis and angiogenesis, further amplifying portal hypertension.[9][10] This multifactorial, self-reinforcing physiology explains why portal hypertension is both a manifestation of advanced liver disease and a central driver of its most life-threatening complications [6][7][8][9][10][11].

**Histopathology**

Histopathology has a limited and largely indirect role in the evaluation of portal hypertension. In routine clinical practice, portal hypertension is primarily a hemodynamic and radiologic diagnosis, supported by endoscopic findings and noninvasive markers rather than by tissue examination. Nevertheless, histopathology becomes relevant in specific circumstances, particularly when a liver biopsy is obtained for another indication—most commonly the investigation of abnormal liver function tests of uncertain cause. In such cases, the biopsy may incidentally reveal early or clinically silent portal hypertensive changes before overt manifestations such as variceal bleeding, ascites, or encephalopathy develop. This reflects an important principle: structural and microvascular alterations within the portal tracts and hepatic sinusoids can evolve gradually and may precede the clinical threshold at which portal hypertension becomes apparent. When portal hypertensive physiology is developing, histologic changes may be observed within both hepatic parenchyma and portal vascular structures. Early fibrotic remodeling is one of the most common findings, ranging from subtle portal or

periportal fibrosis to more advanced bridging fibrosis depending on the underlying etiology. Fibrosis alters hepatic microcirculation by narrowing vascular channels and disturbing sinusoidal architecture, thereby increasing resistance to portal inflow. In addition to fibrotic changes, alterations in the portal venous microvasculature can be seen, including an apparent increase in portal vein branches, which may reflect vascular remodeling, collateralization within portal tracts, or adaptive responses to chronically altered flow dynamics. Thickening of smooth muscle walls in vascular structures has also been described, suggesting chronic hemodynamic stress and remodeling of small portal venules and related vessels. Furthermore, an increase in lymphatic vessels may be identified histologically, consistent with the broader concept that chronic portal hypertension and hepatic inflammation can stimulate lymphangiogenesis and alter fluid handling within the portal triads.[11] Collectively, these findings illustrate that portal hypertension is not merely a pressure abnormality but a disease process with measurable structural correlates at the microscopic level [11].

Despite these potential observations, liver biopsy is not recommended as a primary tool to assess portal hypertension.[11] Several reasons explain this limitation. First, biopsy provides only a small tissue sample and may not capture the heterogeneous distribution of fibrosis and vascular remodeling, particularly in patchy diseases. Second, histologic findings do not reliably quantify portal pressure, grade the severity of portal hypertension, or predict the immediate risk of complications such as variceal hemorrhage with sufficient accuracy for standalone decision-making. Third, the procedure carries risks—especially in patients with advanced liver disease who may have thrombocytopenia or coagulopathy—making invasive sampling undesirable when safer, more informative alternatives exist. Accordingly, histopathology is best viewed as supportive and etiologic: it can clarify the underlying liver disease driving increased resistance, identify noncirrhotic causes of portal hypertension, or reveal early architectural changes, but it should not be used as the principal method for diagnosing or staging portal hypertension itself.[11]

**History and Physical**

The clinical presentation of portal hypertension is frequently silent until complications emerge, reflecting the fact that substantial hemodynamic derangement can develop gradually while hepatic reserve and systemic adaptation initially mask overt symptoms. Consequently, history and physical examination are often most informative when directed toward detecting decompensating events and identifying the characteristic physical stigmata that suggest chronic liver disease and portal-systemic collateralization. In routine clinical practice, portal hypertension is commonly first suspected when a patient presents with a complication such as variceal hemorrhage, ascites, or hepatic encephalopathy, rather than with symptoms attributable to elevated portal pressure itself. Variceal bleeding remains the most dramatic and frequent initial manifestation. Hematemesis—vomiting of fresh blood—is classically associated with bleeding esophageal or gastric varices and is widely regarded as the most common clinical presentation of portal hypertension-related hemorrhage. Melena may occur with or without hematemesis, and a history of black, tarry stools should prompt evaluation for upper gastrointestinal bleeding even in the absence of vomiting blood. Because variceal hemorrhage carries high short-term morbidity and mortality, portal hypertension should be strongly considered in any patient presenting with gastrointestinal bleeding when there are concurrent signs of chronic liver disease. These stigmata include jaundice, gynecomastia, palmar erythema, spider nevi, testicular atrophy, Dupuytren contractures, parotid enlargement, ascites, peripheral (pedal) edema, and neurologic signs of hepatic encephalopathy such as asterixis.[3] Careful history-taking should explore risk factors for chronic liver disease—alcohol use, viral hepatitis exposure, metabolic risk factors, medication and toxin exposure, and family history—while simultaneously clarifying bleeding severity, syncope, anticoagulant use, and prior episodes of gastrointestinal hemorrhage [3][4][[10][11].

Physical examination may provide direct clues to portal-systemic collateral formation, particularly in the abdominal wall. With sustained portal hypertension, paraumbilical veins can recanalize and enlarge, creating visible abdominal wall venous patterns that represent an attempt to decompress the portal circulation by diverting blood into the systemic caval system. The direction of venous flow can be clinically informative. In caput medusae, blood typically flows away from the umbilicus, consistent with portal blood being shunted outward through dilated superficial veins. In contrast, when the inferior vena cava is obstructed, superficial venous flow may be redirected toward the umbilicus as blood seeks alternate routes to reach the superior vena cava.[4] Auscultation may reveal a venous hum near the xiphoid process or the umbilicus, reflecting high-flow collateral channels. Cruveilhier–Baumgarten syndrome specifically describes the combination of dilated abdominal wall veins and a low-pitched venous murmur at the umbilicus, a finding that supports substantial paraumbilical collateralization.[4] By comparison, an arterial systolic murmur over the liver more often suggests hypervascular hepatic pathology such as hepatocellular carcinoma or marked inflammatory hyperemia seen in alcohol-related hepatitis, and its presence should prompt careful diagnostic evaluation rather than being attributed solely to portal hypertension.[4]

Splenomegaly is among the most dependable physical indicators of portal hypertension and should be actively sought during examination.[1] Enlargement of the spleen reflects chronic congestion and increased portal venous pressure transmitted to the splenic vein. Clinically, palpable splenomegaly—particularly when accompanied by thrombocytopenia—supports portal hypertensive physiology, while the absence of splenic enlargement on physical examination or imaging should trigger reconsideration of the diagnosis, especially when portal hypertension is being invoked to explain gastrointestinal bleeding or cytopenias. Hypersplenism may develop as splenic enlargement progresses, leading to pancytopenia. This cytopenia is attributed to reticuloendothelial hyperplasia and sequestration within the enlarged spleen and is notable for its limited reversibility: reductions in portal pressure achieved through portocaval shunting do not reliably normalize blood counts, underscoring that hypersplenism reflects chronic splenic remodeling rather than only the immediate portal pressure state. Examination of the liver and abdomen provides additional supportive information, though findings correlate imperfectly with the degree of portal hypertension. A firm, nodular liver on palpation favors cirrhosis as an underlying cause, yet hepatomegaly itself correlates poorly with portal pressure severity and may be influenced by many factors, including steatosis, congestion, inflammation, or tumor infiltration. Ascites, when present, suggests clinically significant portal hypertension and often indicates decompensation, but ascites can also arise from other processes such as malignancy or cardiac failure, so it must be interpreted alongside other signs and clinical context. Peripheral edema may accompany hypoalbuminemia, renal sodium retention, or heart failure physiology. Neurologic assessment is essential, as subtle cognitive slowing, sleep–wake reversal, or asterixis may signal hepatic encephalopathy and thus advanced portal hypertensive disease with impaired hepatic clearance and systemic neurotoxicity. Overall, the history and physical examination in portal hypertension should be framed as a targeted search for complications and collateralization, coupled with systematic evaluation for chronic liver disease stigmata and alternative etiologies. While patients may remain asymptomatic for prolonged periods, the emergence of variceal bleeding, ascites, or encephalopathy frequently defines the point at which portal hypertension becomes clinically apparent and requires urgent risk stratification and multidisciplinary management.[1][3][4]

**Evaluation**

The evaluation of portal hypertension is a multidisciplinary process that integrates careful clinical history, targeted laboratory testing, advanced imaging, and—in select cases—hemodynamic and endoscopic assessment. The overarching goal is to confirm the presence of elevated portal pressure, determine its severity and etiology, and identify complications requiring intervention. Because portal hypertension is often secondary to chronic liver disease, many diagnostic clues emerge from assessing hepatic function, synthetic capacity, and structural abnormalities rather than directly measuring portal venous pressure.

**Laboratory Studies**

Laboratory evaluation begins with a comprehensive metabolic and hematologic workup to assess liver function, identify complications, and exclude alternative diagnoses. A complete blood count (CBC) provides key information about cytopenias: thrombocytopenia is common and often represents hypersplenism due to splenic sequestration, whereas anemia may suggest chronic gastrointestinal blood loss from varices or portal hypertensive gastropathy. Leukopenia, also related to hypersplenism, can indicate advanced disease. A comprehensive metabolic panel (CMP) evaluates hepatic and renal status. Elevated aminotransferases (AST, ALT) may indicate hepatocellular injury, while alkaline phosphatase and gamma-glutamyl transferase (GGT) elevations point toward cholestasis. Bilirubin elevation and hypoalbuminemia reflect diminished hepatic synthetic and excretory capacity. Serum creatinine and blood urea nitrogen (BUN) levels should also be monitored, as renal dysfunction commonly accompanies advanced cirrhosis due to hepatorenal physiology or prerenal hypoperfusion. A coagulation profile (prothrombin time, INR, and partial thromboplastin time) further characterizes hepatic synthetic function. The liver synthesizes most clotting factors; thus, a prolonged prothrombin time (PT) or elevated INR is an early marker of decompensated hepatic function. Combined with low serum albumin, these findings are incorporated into prognostic scoring systems such as the Child–Pugh and MELD scores, which aid in assessing disease severity and guiding transplant evaluation. When results suggest advanced hepatic dysfunction, further serologic workup for viral hepatitis (HBV, HCV), autoimmune hepatitis, hemochromatosis, Wilson's disease, or alpha-1 antitrypsin deficiency may help clarify etiology [11][12].

**Imaging Studies**

Imaging plays a central role in both the diagnosis and risk stratification of portal hypertension. Noninvasive modalities can identify hallmark signs—splenomegaly, ascites, and the presence of portosystemic collaterals—that indirectly reflect elevated portal venous pressure. Abdominal ultrasound is typically the first-line imaging test. It can reveal cirrhotic liver morphology (nodular contour, altered echotexture), splenomegaly, ascites, and collateral veins. Importantly, Doppler ultrasound

assesses blood flow direction and velocity in the portal vein. Normal flow is hepatopetal (toward the liver), whereas hepatofugal flow (away from the liver) indicates advanced portal hypertension. Doppler ultrasonography also detects portal vein thrombosis, stenosis, or other prehepatic causes. It can assess hepatic vein patency and identify signs of Budd–Chiari syndrome or inferior vena cava obstruction. Contrast-enhanced computed tomography (CT) provides a broader view of hepatic and splanchnic anatomy, delineating the liver's size and shape, collateral circulation, and splenic enlargement. CT can also detect varices, ascites, and malignancies, such as hepatocellular carcinoma, that may contribute to portal hypertension. Magnetic resonance imaging (MRI)—especially with Gadolinium enhancement—can noninvasively identify esophageal and gastric varices, delineate vascular anatomy, and assess liver stiffness or fibrosis when elastography sequences are included.[12][13]

**Endoscopic Evaluation**

Endoscopy remains essential for detecting and managing varices, one of the most significant complications of portal hypertension. All patients with cirrhosis require evaluation for clinically significant portal hypertension (CSPH). In patients who can tolerate it, therapy with a nonselective beta-blocker (NSBB) such as propranolol, nadolol, or carvedilol is recommended as primary prophylaxis against variceal bleeding. If NSBBs are contraindicated or not tolerated, screening upper endoscopy is indicated to identify esophageal or gastric varices requiring prophylactic ligation or pharmacologic therapy.[14] If no varices are detected, endoscopic surveillance should be repeated every 2 to 3 years, depending on clinical status, rate of hepatic disease progression, and ongoing risk factors such as alcohol use or viral hepatitis.[15] When varices are identified and classified as large, primary prophylaxis should be initiated with NSBBs or endoscopic variceal ligation. Patients with ascites should undergo diagnostic paracentesis to determine the cause and exclude spontaneous bacterial peritonitis (SBP), a potentially fatal infection unique to portal hypertensive ascites.[16][17]




**Fig. 3:** Computed tomography of portal hypertension.

**Invasive Hemodynamic Assessment**

In patients with clear clinical or imaging evidence of portal hypertension, direct portal pressure measurement is seldom required for routine management. However, in uncertain cases or research settings, the hepatic venous pressure gradient (HVPG) provides the most accurate hemodynamic assessment. Measurement involves hepatic vein catheterization, determining both free hepatic vein pressure (FHVP) and wedged hepatic vein pressure (WHVP). The HVPG is the difference between these values (HVPG = WHVP − FHVP). Normal HVPG is ≤5 mm Hg; values ≥6 mm Hg indicate portal hypertension, and ≥10 mm Hg denotes clinically significant portal hypertension. Complications such as variceal bleeding usually occur when HVPG exceeds 12 mm Hg.[18] Despite its diagnostic precision, HVPG measurement is limited to specialized centers due to procedural complexity, invasiveness, and cost. It is primarily reserved for research studies, prognostic assessment in chronic liver disease, or when the diagnosis is uncertain and may alter management [17][18].

**Noninvasive Elastography and Emerging Techniques**

Transient elastography, a noninvasive ultrasound-based method, estimates liver stiffness by measuring the velocity of shear waves passing through hepatic tissue. Liver stiffness correlates with fibrosis stage and indirectly with portal pressure, making elastography a valuable tool for identifying patients at risk of CSPH.[19] Elevated liver stiffness values—typically >20–25 kPa—strongly predict portal hypertension and correlate with the presence of esophageal varices and splenomegaly. This approach offers a practical alternative for stratifying patients in whom invasive pressure measurements are not feasible. In addition to elastography, newer magnetic resonance elastography (MRE) and acoustic radiation force impulse (ARFI) imaging techniques are expanding the noninvasive diagnostic arsenal. These modalities can assess liver and spleen stiffness simultaneously, with spleen stiffness providing complementary insight into the severity of portal hypertension. Diagnosis of portal hypertension rarely depends on a single test; instead, it rests on integrating clinical, laboratory, and imaging findings. For instance, the combination of thrombocytopenia, splenomegaly, and varices is virtually diagnostic in the context of chronic liver disease. Conversely, when the liver appears morphologically normal, prehepatic causes such as portal vein thrombosis or posthepatic causes such as Budd–Chiari syndrome must be considered, and Doppler ultrasound or CT angiography becomes crucial. According to recent American Association for the Study of Liver Diseases (AASLD) guidance, patients with chronic liver disease and suspected CSPH should be stratified using noninvasive tools first, reserving HVPG measurement or endoscopic screening for those meeting defined risk thresholds.[20] Elastography, platelet count, and imaging features (e.g., splenomegaly, collaterals) together guide the need for

further testing and initiation of prophylactic therapies. Comprehensive evaluation of portal hypertension requires a stepwise, evidence-based approach. Laboratory studies assess hepatic function and systemic effects such as cytopenias and coagulopathy; imaging delineates vascular anatomy and complications; endoscopy identifies varices; and elastography provides noninvasive risk stratification. Invasive pressure measurement remains the reference standard but is reserved for select cases. By integrating these modalities, clinicians can confirm portal hypertension, assess its severity, guide therapy, and monitor disease progression—all while minimizing procedural risk and ensuring patient-centered care.[12][13][14][15][16][17][18][19][20]

**Treatment / Management**

Management of portal hypertension is optimally conceptualized as a dual-track strategy that simultaneously targets (1) the underlying etiology responsible for increased portal venous resistance and/or inflow and (2) the prevention and treatment of portal hypertension–related complications. This approach reflects the hemodynamic reality that portal hypertension is not a diagnosis in isolation but rather a final common pathway of diverse hepatic and extrahepatic disorders. Accordingly, effective care requires etiologic precision, early risk stratification for clinically significant portal hypertension (CSPH), and proactive deployment of therapies that reduce portal pressure and prevent decompensation.

**Management of portal hypertension etiologies**

The first obligation in management is to identify reversible drivers of elevated portal pressure and pursue corrective therapy whenever feasible. In prehepatic portal hypertension, particularly portal vein thrombosis (PVT) or inferior vena cava thrombosis in the setting of a hypercoagulable state, anticoagulation may be the treatment of choice because it can prevent thrombus propagation, promote recanalization in selected patients, and reduce progression of portal hypertensive sequelae. In practice, decisions regarding anticoagulation must incorporate bleeding risk, the presence of varices, platelet count, and the chronicity and extent of thrombosis, with close collaboration between internal medicine, hepatology, and (when needed) interventional radiology. When thrombosis occurs in association with cirrhosis, anticoagulation can still be appropriate in carefully selected cases, and it is increasingly considered within multidisciplinary pathways that include endoscopic evaluation and portal pressure–reducing therapies. In intrahepatic portal hypertension, etiologic therapy is often synonymous with chronic liver disease management. Viral hepatitis is a clear example in which disease-modifying treatment can meaningfully alter the portal hypertension trajectory. For hepatitis C infection, initiation of antiviral therapy may prevent disease progression, reduce hepatocellular carcinoma risk, and delay the development of clinically significant portal hypertension and variceal bleeding. In metabolic dysfunction–associated steatotic liver disease, alcohol-associated liver disease, and autoimmune hepatitides, sustained etiologic control (weight loss and metabolic optimization, strict alcohol abstinence, immunosuppression when indicated) can stabilize or partially reverse fibrosis, thereby improving portal resistance over time. Although regression of portal hypertension is not guaranteed, etiologic control remains foundational because it modifies the disease substrate that drives portal pressure elevation [17][18][19].

Posthepatic portal hypertension demands a different corrective emphasis. Budd–Chiari syndrome requires urgent evaluation of hepatic venous outflow obstruction, typically combining anticoagulation, treatment of the underlying prothrombotic disorder, and—when necessary—endovascular or shunt-based interventions. When portal hypertension is secondary to constrictive pericarditis, severe tricuspid regurgitation, or restrictive cardiomyopathy, the effective “portal hypertension therapy” is correction of the cardiac lesion and reduction of right-sided filling pressures. In these patients, the pattern of ascites, hepatomegaly, peripheral edema, and imaging evidence of hepatic congestion should trigger joint management between hepatology and cardiology, because purely liver-directed interventions may be inadequate if venous outflow remains constrained [1].

**Medical therapy to reduce portal pressure and prevent decompensation**

Nonselective beta-blockers (NSBBs) remain central pharmacologic tools in portal hypertension because they lower portal pressure by reducing portal venous inflow. Mechanistically, NSBBs reduce cardiac output through β1 blockade and decrease splanchnic vasodilation through β2 blockade, thereby reducing splanchnic blood flow and portal inflow, with a consequent reduction in hepatic venous pressure gradient (HVPG).[2] Contemporary practice has increasingly emphasized carvedilol because it combines NSBB effects with additional α1-adrenergic antagonism, producing greater splanchnic vasoconstriction and more substantial portal pressure reduction in many patients. The recent AASLD portal hypertension practice guidance endorses NSBBs—preferably carvedilol—as prophylactic therapy for patients with CSPH to reduce the risk of first decompensation and portal hypertensive bleeding. A commonly referenced carvedilol initiation strategy is 6.25 mg daily, with escalation to 12.5 mg/day (often divided) if tolerated after several days, while monitoring for hypotension and bradycardia; dose reduction is typically considered if systolic blood pressure falls below 90 mm Hg or if clinically significant dizziness, renal hypoperfusion, or fatigue develops.[21] The clinical point is not the arithmetic of dosing alone, but the disciplined titration

framework: portal pressure reduction must be balanced against systemic hemodynamics, renal perfusion, and the "therapeutic window" in advanced cirrhosis. When carvedilol is not tolerated, alternative NSBBs (e.g., propranolol or nadolol) or endoscopic strategies may be required, tailored to the patient's risk profile and comorbidities [2][20][21]. A notable paradigm shift in modern guidance is that early NSBB use in appropriate patients with CSPH may reduce or even obviate the need for screening endoscopy in many cases, because management would not change if pharmacologic prophylaxis is already indicated and implemented. This strategy is not "endoscopy avoidance" as an ideology; rather, it is a risk-based allocation of invasive testing, prioritizing endoscopy for patients in whom variceal characterization will change management (for example, those unable to take NSBBs, those with prior bleeding, or those being evaluated for endoscopic eradication therapy) [22][23][24][25].

**Risk management and prevention of complications**

After etiologic assessment and portal pressure–lowering therapy are addressed, management focuses on preventing complications and treating them promptly when present. The dominant complication domains include gastroesophageal varices and bleeding, ascites and its infectious sequelae, hepatic encephalopathy, and portal vein thrombosis. In family medicine and internal medicine settings, this phase is heavily dependent on longitudinal surveillance, vaccination and lifestyle counseling, medication reconciliation, and early referral when decompensation emerges.

**Acute variceal bleeding**

Acute variceal hemorrhage is a life-threatening emergency requiring immediate, protocolized care. Current standard-of-care bundles emphasize four simultaneous priorities: restrictive transfusion strategy, vasoactive therapy, prophylactic antibiotics, and urgent endoscopic intervention. A restrictive transfusion strategy is recommended, with packed red blood cell transfusion performed conservatively to a target hemoglobin typically in the 7–8 g/dL range, while individualizing to the patient's age, cardiovascular disease, hemodynamic status, and ongoing bleeding. This principle is clinically important because over-transfusion can increase portal pressure and worsen bleeding risk, whereas under-resuscitation risks shock and end-organ ischemia. Simultaneously, vasoactive agents that reduce splanchnic blood flow—such as terlipressin, somatostatin, or octreotide—should be initiated early because they lower portal inflow and support hemostasis. The regimen details frequently used in practice (e.g., octreotide bolus followed by infusion for several days, or terlipressin dosing until hemostasis) align with guideline-endorsed concepts that vasoactive therapy should begin as soon as variceal bleeding is suspected and continue for several days after endoscopic control to reduce early rebleeding risk.[26][27][28] Prophylactic antibiotics are not ancillary; they are a core component of acute management because bacterial infections and spontaneous bacterial peritonitis (SBP) are common in this setting and worsen outcomes. AASLD guidance describes prophylactic antibiotics as part of the standard acute bleeding package, and ceftriaxone is commonly recommended in hospitalized patients, with later transition to appropriate oral regimens when clinically suitable. Endoscopy should be performed urgently—often within 12 hours of presentation after stabilization—because endoscopic variceal ligation (EVL) is the primary definitive therapy for esophageal variceal bleeding and is also used prophylactically for high-risk varices. When bleeding persists despite optimal pharmacologic and endoscopic therapy, or when the patient meets criteria for high early treatment failure risk, transjugular intrahepatic portosystemic shunt (TIPS) becomes a critical escalation option. The AASLD practice guidance on TIPS and related interventions emphasizes that standard-of-care therapy includes restrictive transfusion, vasoactive drugs, prophylactic antibiotics, and EVL, and it addresses the role of TIPS when rebleeding occurs early or when high-risk profiles justify preemptive intervention [26][27][28].

TIPS works by creating a low-resistance channel between intrahepatic portal and hepatic venous branches, thereby decompressing the portal system and reducing variceal pressure. However, the hemodynamic benefit is coupled to physiologic trade-offs: by diverting blood away from hepatic sinusoids, TIPS can reduce hepatic clearance of ammonia and other neurotoxins, increasing the risk of hepatic encephalopathy, and may precipitate liver failure in patients with limited hepatic reserve. Thus, TIPS candidacy requires careful assessment of liver function, encephalopathy history, cardiac status, and procedural risk, typically coordinated through hepatology and interventional radiology [28].

**Ascites and related complications**

Ascites management is another cornerstone of portal hypertension treatment and is best approached as staged therapy guided by severity and response. Initial management typically includes dietary sodium restriction and diuretic therapy—commonly spironolactone in combination with furosemide—to promote natriuresis while limiting electrolyte derangements.[31] Monitoring is not optional: serial weights, blood pressure, serum sodium, potassium, and renal function guide safe titration, and outpatient follow-up is crucial to avoid iatrogenic kidney injury or severe hyponatremia. When ascites is tense, symptomatic, or refractory to diuretics, large-volume paracentesis becomes a key therapeutic intervention, usually paired with albumin replacement in high-volume removal to mitigate post-paracentesis circulatory dysfunction. In patients with refractory ascites or recurrent large-volume

requirements, TIPS may reduce ascites recurrence by lowering portal pressure, but it again requires careful selection due to encephalopathy and cardiac risk. Ultimately, liver transplantation remains the definitive therapy for portal hypertension caused by cirrhosis, particularly when ascites reflects decompensated disease and is accompanied by worsening synthetic function, recurrent hospitalizations, or other complications.[31] Diagnostic paracentesis is equally important in any patient with new-onset ascites, clinical deterioration, fever, abdominal pain, encephalopathy, or renal dysfunction, because SBP can present subtly yet carries high mortality without prompt antibiotic therapy.[16][17] This diagnostic discipline belongs not only to hepatology but to emergency medicine, internal medicine wards, and family medicine triage pathways, as early sampling and treatment materially change outcomes [17][18][29][30][31].

**Longitudinal management, coordination, and definitive therapy**

Because portal hypertension is often chronic and progressive, long-term management requires continuous reassessment of risk, adherence, and candidacy for escalation therapies. This includes optimizing nutrition, avoiding alcohol, managing sarcopenia, vaccinating appropriately, reviewing medications for nephrotoxicity and bleeding risk, and ensuring structured surveillance for hepatocellular carcinoma and variceal progression. In patients with cirrhosis, the transition from compensated to decompensated disease is the inflection point at which transplant evaluation should be considered, because transplantation is the only intervention that reliably removes the underlying substrate of cirrhosis and resolves portal hypertension at its source. In summary, treatment of portal hypertension integrates etiologic correction when possible (e.g., anticoagulation for thrombosis, antiviral therapy for hepatitis C), portal pressure reduction—preferably with carvedilol in appropriate patients with CSPH per recent AASLD guidance and complication-focused pathways for variceal bleeding, ascites, infection prevention, and escalation to TIPS or transplantation when clinically indicated [31].

**Differential Diagnosis**

The differential diagnosis of portal hypertension is best approached as a structured evaluation of conditions that either elevate portal inflow, obstruct portal venous channels, increase intrahepatic vascular resistance, or impair hepatic venous outflow and right-sided cardiac drainage. Although cirrhosis is the most common cause in many regions, clinicians must avoid assuming cirrhosis whenever varices, ascites, or splenomegaly are present, because important noncirrhotic etiologies may produce similar complications while requiring fundamentally different management. The most clinically consequential alternatives can be grouped into hepatic venous outflow obstruction syndromes, cardiac causes of posthepatic congestion, hematologic disorders predisposing to thrombosis, and infiltrative or systemic diseases that alter hepatic microvasculature. Budd–Chiari syndrome is a high-priority diagnosis because hepatic venous outflow obstruction can present with painful hepatomegaly, ascites, and portal hypertensive features, and early anticoagulation or endovascular intervention can be life-saving. Constrictive pericarditis and severe tricuspid regurgitation should also be considered, particularly when portal hypertension coexists with peripheral edema, jugular venous distension, or imaging evidence of hepatic congestion; these posthepatic causes elevate right atrial and hepatic venous pressures and may mimic cirrhosis-associated ascites yet require cardiology-directed therapy rather than purely liver-centered management. Myeloproliferative disease is another critical diagnostic consideration because it creates a prothrombotic milieu that can precipitate portal vein thrombosis or hepatic vein thrombosis, generating prehepatic or posthepatic portal hypertension that may be reversible with anticoagulation and targeted hematologic therapy. Polycystic kidney disease can contribute through associated hepatic cyst burden and vascular complications, occasionally complicating portal flow dynamics or coexisting with thrombotic disorders, and it often requires a combined nephrology–hepatology approach [30][31].

Systemic inflammatory and granulomatous conditions such as sarcoidosis and tuberculosis can cause intrahepatic presinusoidal portal hypertension through granulomatous infiltration and portal tract remodeling, sometimes with relatively preserved synthetic liver function, which may lead to diagnostic uncertainty if clinicians equate portal hypertension solely with cirrhosis. Finally, toxin- or nutrient-related injury patterns must be considered; excessive vitamin A exposure has been linked to hepatic injury and vascular remodeling that can produce portal hypertension, while “vitamin A deficiency” is not a typical cause and should prompt re-evaluation of history for hepatotoxic exposures, malabsorption syndromes, or documentation errors. In aggregate, this differential highlights the importance of integrating risk factors, laboratory synthetic function, Doppler flow assessment, and cross-sectional imaging to localize the site of resistance and avoid misclassification of potentially treatable causes [30].

**Prognosis**

The prognosis of portal hypertension is primarily determined by three interacting variables: the underlying etiology, the severity of hepatic dysfunction, and the presence and recurrence of complications. Portal hypertension itself is a hemodynamic syndrome, but its clinical consequences—particularly variceal bleeding, refractory ascites, spontaneous bacterial peritonitis,

hepatorenal syndrome, and hepatic encephalopathy—drive hospitalization, reduce quality of life, and increase mortality. Prognostic stratification is therefore inseparable from staging of chronic liver disease and from distinguishing compensated portal hypertension from clinically significant portal hypertension (CSPH), which has a substantially higher probability of decompensation. From a hemodynamic standpoint, thresholds of hepatic venous pressure gradient (HVPG) correlate with risk. Patients with HVPG ≥10 mm Hg—defining CSPH—face a markedly increased likelihood of first decompensating events, including ascites, encephalopathy, and variceal development. As portal pressure rises further, clinical risk becomes more acute; when HVPG reaches ≥12 mm Hg, the probability of life-threatening variceal hemorrhage and other severe complications increases sharply, reflecting the transition from "risk of formation" to "risk of rupture" in portal-systemic collaterals. Prognosis is also shaped by the dynamic trajectory of liver disease: patients with stable compensated cirrhosis and controlled portal pressure may remain clinically well for years, whereas those with progressive fibrosis, ongoing alcohol use, uncontrolled viral hepatitis, or recurrent inflammatory triggers often progress rapidly to decompensation and repeated hospital admissions [30][31].

Early identification and evidence-based management can meaningfully improve outcomes. Etiology-directed therapies—such as antivirals for hepatitis C or B, anticoagulation for thrombotic causes, and cardiac intervention for posthepatic congestion—can stabilize or reverse portal pressure drivers in selected cases. Preventive strategies, including nonselective beta-blockers and endoscopic management of high-risk varices, reduce the probability of first bleeding and recurrent hemorrhage, thereby lowering short-term mortality and limiting downstream decompensation. Abstinence from alcohol is especially prognostically powerful in alcohol-associated liver disease, as it can improve inflammation, enhance synthetic function, and in some patients reduce portal hypertensive severity over time. However, when disease is advanced or complications become refractory, prognosis worsens and escalation therapies—TIPS for recurrent bleeding or refractory ascites, and ultimately liver transplantation—become central. Transplantation remains the definitive treatment for cirrhosis-related portal hypertension because it removes the structural substrate producing increased resistance. Conversely, delayed diagnosis or inadequate management leads to higher rates of bleeding, infection, renal failure, intensive care utilization, and mortality, and it increases the likelihood that patients will require urgent transplant evaluation under less favorable physiologic conditions [31].

**Complications**

Complications of portal hypertension reflect the systemic consequences of sustained portal pressure elevation, splanchnic vasodilation, collateral vessel formation, and progressive hepatic dysfunction. Many complications arise directly from decompressive collateralization: gastroesophageal varices are the most recognized, but clinically important varices can also occur in the anorectal region, retroperitoneum, stoma sites, and other ectopic locations. Variceal hemorrhage is the most feared acute complication because it can produce rapid hemodynamic instability and death without timely resuscitation, vasoactive therapy, antibiotics, and endoscopic control. Even in the absence of massive bleeding, chronic low-grade blood loss from portal hypertensive gastropathy or enteropathy may lead to iron deficiency anemia, fatigue, and recurrent transfusion needs, particularly when coagulopathy, thrombocytopenia, or anticoagulation complicate hemostasis. Hypersplenism is another common consequence of portal hypertension, with splenic congestion leading to thrombocytopenia and, in some cases, pancytopenia. These cytopenias are not merely laboratory abnormalities; they influence procedural risk, complicate anticoagulation decisions, and can delay necessary interventions. Ascites represents a cardinal decompensating event and often marks a major prognostic inflection point. Ascites predisposes to spontaneous bacterial peritonitis, a life-threatening infection that may present subtly with fever, abdominal discomfort, encephalopathy, or renal dysfunction and requires prompt diagnostic paracentesis and empiric antibiotics. Advanced portal hypertension can also produce hepatic hydrothorax, where pleural effusions—typically right-sided—result from transdiaphragmatic movement of ascitic fluid, complicating ventilation and frequently recurring despite standard diuretic therapy. Multi-organ syndromes further define severe disease. Hepatorenal syndrome reflects functional renal failure driven by profound circulatory dysregulation and renal vasoconstriction; hepatic encephalopathy results from impaired detoxification and altered neuroinflammation; hepatopulmonary syndrome arises from intrapulmonary vascular dilatations causing hypoxemia; and portopulmonary hypertension reflects pulmonary vascular remodeling that increases right heart strain. Cirrhotic cardiomyopathy can coexist, reducing cardiovascular reserve and complicating TIPS candidacy or transplant evaluation. Together, these complications illustrate that portal hypertension is not an isolated vascular phenomenon but a systemic disorder with interdependent organ effects, where early prevention of first decompensation is often more impactful than repeated rescue therapy after complications recur [31].

**Consultations**

Effective management of portal hypertension typically requires interprofessional consultation because the syndrome crosses multiple organ systems and often demands both preventive and rescue interventions. Gastroenterology and hepatology are central for confirming etiology, staging liver disease, initiating portal pressure–lowering therapy, and coordinating endoscopic surveillance and treatment of varices. Interventional radiology becomes essential when advanced procedures are considered, particularly TIPS placement, portal vein recanalization strategies in selected thrombotic cases, or image-guided paracentesis in patients with complex ascites. Nephrology is frequently involved when renal dysfunction emerges, whether due to hepatorenal syndrome, diuretic-related kidney injury, hyponatremia, or the need to balance volume management with renal perfusion. Cardiology consultation is often indicated when posthepatic causes are suspected—such as constrictive pericarditis or significant tricuspid regurgitation—or when patients are being evaluated for TIPS or transplantation and require cardiac risk assessment. Pulmonology may be required for suspected hepatopulmonary syndrome or portopulmonary hypertension, conditions that substantially influence transplant candidacy and perioperative risk. Hematology consultation is appropriate when myeloproliferative disease or other hypercoagulable states drive portal or hepatic vein thrombosis, because long-term anticoagulation strategy and disease-directed therapy can alter outcomes. Finally, transplant hepatology is crucial for patients with recurrent decompensation, refractory ascites, recurrent bleeding, or deteriorating synthetic function, ensuring that referral is not delayed until the patient becomes too frail or unstable to benefit from definitive therapy [31].

**Patient Education**

Deterrence and prevention of portal hypertension begin with addressing modifiable risk factors and implementing early, sustained management of chronic liver disease to prevent fibrosis progression and the development of CSPH. Lifestyle interventions are foundational. Patients should be strongly counseled to abstain from alcohol, as continued alcohol exposure accelerates fibrosis, increases portal pressure, and precipitates decompensation. Weight management, glycemic control in diabetes, and treatment of dyslipidemia are similarly important, particularly in metabolic dysfunction–associated liver disease, where progressive fibrosis can be slowed or reversed through sustained metabolic improvement. Vaccination, medication reconciliation, and avoidance of unnecessary hepatotoxic agents also serve as preventive pillars, reducing the likelihood of acute-on-chronic liver injury that can abruptly worsen portal hypertension. Etiology-specific prevention is equally critical. Early diagnosis and treatment of hepatitis B or C can prevent progression to cirrhosis, thereby reducing long-term portal hypertensive risk. For patients with known prothrombotic disorders, counseling should include the rationale for anticoagulation when indicated and the need for regular follow-up, because portal vein thrombosis can represent a reversible prehepatic driver when addressed early. Patients should also be educated to avoid hepatotoxic substances and exposures associated with noncirrhotic portal hypertension, including excessive vitamin A, arsenic, and certain chemotherapeutic agents such as oxaliplatin, particularly when alternative regimens exist. Patient education should also emphasize recognition of complications and timely escalation. Individuals and families must understand warning signs of gastrointestinal bleeding (hematemesis, melena, presyncope), hepatic encephalopathy (confusion, sleep–wake reversal, asterixis), and ascites complications (fever, abdominal pain, rapid abdominal distension). Education should include the importance of routine monitoring—such as laboratory assessment of synthetic function, noninvasive fibrosis and portal hypertension risk tools, and endoscopic screening when indicated—because many catastrophic events are preventable through early prophylaxis. Patients should be supported in medication adherence, particularly with nonselective beta-blockers, and counseled on dietary sodium restriction and diuretic safety when ascites is present. Clear “when to seek urgent care” instructions are essential, as delays in presentation during bleeding or encephalopathy episodes markedly worsen outcomes [31].

**Other Issues**

Several clinical pearls summarize high-yield principles. Cirrhosis is the dominant cause of portal hypertension in Western countries, but noncirrhotic causes—particularly schistosomiasis and portal vein thrombosis—account for a substantial burden in other regions, so geographic and exposure history should shape diagnostic reasoning. Portal hypertension can remain clinically silent until complications develop; therefore, relying on symptoms alone delays diagnosis and misses the window for preventive therapy. Noninvasive methods frequently allow diagnosis and risk stratification, especially when physical findings (splenomegaly, ascites, collateral veins), laboratory patterns (thrombocytopenia, hypoalbuminemia), and imaging evidence (collaterals, portal vein flow changes) converge. Transient elastography, platelet count, and imaging markers can often identify patients at risk for CSPH and guide prophylactic strategies without invasive HVPG measurement in many settings. When HVPG measurement is available, it provides powerful

prognostic information and helps define CSPH thresholds relevant to preventive therapy, but it is not required in most routine cases. Finally, always interpret portal hypertension in a systems context: renal function, infection risk, cardiopulmonary status, and nutrition frequently determine outcomes as much as portal pressure itself [31].

**Enhancing Healthcare Team Outcomes**

Optimizing outcomes in portal hypertension requires coordinated interprofessional care because the condition is complex, progressive, and capable of precipitating rapid decompensation across multiple organ systems. Physicians—spanning primary care, gastroenterology, hepatology, and interventional radiology—share responsibility for diagnosis, staging, and treatment planning. Primary care and family medicine clinicians are often the first to detect early liver disease, counsel on alcohol cessation and metabolic risk, and ensure vaccination and screening follow-through, while hepatology leads portal hypertension staging, NSBB initiation, and transplant referral timing. Interventional radiologists provide procedural expertise for TIPS, vascular interventions, and image-guided therapies, and their input is essential for selecting appropriate candidates and anticipating complications such as encephalopathy or cardiac decompensation. Advanced practitioners contribute continuity by monitoring symptoms, labs, and adherence; reinforcing sodium restriction and medication plans; and facilitating early referral when ascites, encephalopathy, or renal dysfunction emerges. Pharmacists improve safety by adjusting drug regimens for hepatic impairment, identifying drug–drug interactions, counseling on NSBB titration and diuretic monitoring, and supporting anticoagulation management in thrombotic causes. Nurses provide frontline monitoring during admissions for bleeding or infection, deliver patient education, recognize early encephalopathy or volume shifts, and support psychosocial needs that influence adherence and relapse risk. Dietitians play a pivotal role in balancing sodium restriction with adequate protein and caloric intake, reducing sarcopenia and frailty that worsen outcomes and transplant candidacy. Cardiology and pulmonology input becomes critical in portopulmonary hypertension, hepatopulmonary syndrome, and cirrhotic cardiomyopathy, conditions that strongly influence procedural and transplant risk. Interprofessional communication—through shared protocols, standardized order sets for variceal bleeding and ascites, and synchronized electronic health records—reduces fragmentation and prevents delays in escalation. Regular multidisciplinary reviews help align surveillance schedules, medication plans, and referral triggers. When every team member is empowered to identify subtle deterioration and communicate promptly, complications are treated earlier, hospitalizations become more efficient, and patient-centered outcomes improve across the chronic trajectory of portal hypertension.

**Conclusion:**

Portal hypertension represents a central pathophysiologic mechanism in advanced liver disease and a major determinant of clinical outcomes. Its progression from subclinical stages to clinically significant portal hypertension marks the transition from compensated to decompensated cirrhosis, with escalating risks of variceal hemorrhage, ascites, and encephalopathy. Prognosis is strongly linked to underlying etiology, hepatic reserve, and complication burden. Early identification through noninvasive tools and timely initiation of preventive therapy—particularly nonselective beta-blockers—can delay or prevent first decompensation. Etiology-directed interventions, such as antiviral therapy for hepatitis or anticoagulation for thrombotic causes, remain foundational. When complications occur, standardized bundles for acute variceal bleeding, ascites management, and infection prevention are essential, while TIPS and liver transplantation provide definitive options for refractory disease. Longitudinal care demands interprofessional coordination, patient education, and lifestyle modification to mitigate progression and optimize transplant candidacy. Ultimately, portal hypertension is not merely a vascular abnormality but a systemic disorder requiring proactive, multidisciplinary management to improve survival and quality of life.

**References:**

1. Mauro E, Gadano A. What's new in portal hypertension? Liver international : official journal of the International Association for the Study of the Liver. 2020 Feb:40 Suppl 1():122-127. doi: 10.1111/liv.14366.
2. Gunarathne LS, Rajapaksha H, Shackel N, Angus PW, Herath CB. Cirrhotic portal hypertension: From pathophysiology to novel therapeutics. World journal of gastroenterology. 2020 Oct 28:26(40):6111-6140. doi: 10.3748/wjg.v26.i40.6111.
3. Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. JHEP reports : innovation in hepatology. 2021 Aug:3(4):100316. doi: 10.1016/j.jhepr.2021.100316.
4. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology (Baltimore, Md.). 1988 Sep-Oct:8(5):1151-7
5. García-Pagán JC, Gracia-Sancho J, Bosch J. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. Journal of hepatology. 2012 Aug:57(2):458-61. doi: 10.1016/j.jhep.2012.03.007.
6. Kulkarni AV, Rabiee A, Mohanty A. Management of Portal Hypertension. Journal of

clinical and experimental hepatology. 2022 Jul-Aug:12(4):1184-1199. doi: 10.1016/j.jceh.2022.03.002.
7. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. The New England journal of medicine. 2011 Jul 14:365(2):147-56. doi: 10.1056/NEJMra1011170.
8. Turco L, Schepis F, Villa E. The Role of Anticoagulation in Treating Portal Hypertension. Current hepatology reports. 2018:17(3):200-208. doi: 10.1007/s11901-018-0406-x.
9. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology (Baltimore, Md.). 2005 Mar:41(3):422-33
10. Mehta G, Gustot T, Mookerjee RP, Garcia-Pagan JC, Fallon MB, Shah VH, Moreau R, Jalan R. Inflammation and portal hypertension - the undiscovered country. Journal of hepatology. 2014 Jul:61(1):155-63. doi: 10.1016/j.jhep.2014.03.014.
11. Roskams T, Baptista A, Bianchi L, Burt A, Callea F, Denk H, De Groote J, Desmet V, Hubscher S, Ishak K, MacSween R, Portmann B, Poulson H, Scheuer P, Terracciano L, Thaler H. Histopathology of portal hypertension: a practical guideline. Histopathology. 2003 Jan:42(1):2-13
12. Tchelepi H, Ralls PW, Radin R, Grant E. Sonography of diffuse liver disease. Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine. 2002 Sep:21(9):1023-32; quiz 1033-4
13. Willmann JK, Weishaupt D, Böhm T, Pfammatter T, Seifert B, Marincek B, Bauerfeind P. Detection of submucosal gastric fundal varices with multi-detector row CT angiography. Gut. 2003 Jun:52(6):886-92
14. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W, Practice Guidelines Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology (Baltimore, Md.). 2007 Sep:46(3):922-38
15. Grace ND, Groszmann RJ, Garcia-Tsao G, Burroughs AK, Pagliaro L, Makuch RW, Bosch J, Stiegmann GV, Henderson JM, de Franchis R, Wagner JL, Conn HO, Rodes J. Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology (Baltimore, Md.). 1998 Sep:28(3):868-80
16. Diaz KE, Schiano TD. Evaluation and Management of Cirrhotic Patients Undergoing Elective Surgery. Current gastroenterology reports. 2019 Jun 15:21(7):32. doi: 10.1007/s11894-019-0700-y.
17. Alukal JJ, Thuluvath PJ. Gastrointestinal Failure in Critically Ill Patients With Cirrhosis. The American journal of gastroenterology. 2019 Aug:114(8):1231-1237. doi: 10.14309/ajg.0000000000000226.
18. Berzigotti A, Seijo S, Reverter E, Bosch J. Assessing portal hypertension in liver diseases. Expert review of gastroenterology & hepatology. 2013 Feb:7(2):141-55. doi: 10.1586/egh.12.83.
19. Vizzutti F, Arena U, Romanelli RG, Rega L, Foschi M, Colagrande S, Petrarca A, Moscarella S, Belli G, Zignego AL, Marra F, Laffi G, Pinzani M. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology (Baltimore, Md.). 2007 May:45(5):1290-7
20. Sterling RK, Duarte-Rojo A, Patel K, Asrani SK, Alsawas M, Dranoff JA, Fiel MI, Murad MH, Leung DH, Levine D, Taddei TH, Taouli B, Rockey DC. AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis. Hepatology (Baltimore, Md.). 2025 Feb 1:81(2):672-724. doi: 10.1097/HEP.0000000000000843.
21. Sinagra E, Perricone G, D'Amico M, Tinè F, D'Amico G. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis. Alimentary pharmacology & therapeutics. 2014 Mar:39(6):557-68. doi: 10.1111/apt.12634.
22. Kaplan DE, Ripoll C, Thiele M, Fortune BE, Simonetto DA, Garcia-Tsao G, Bosch J. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology (Baltimore, Md.). 2024 May 1:79(5):1180-1211. doi: 10.1097/HEP.0000000000000647.
23. Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. Journal of hepatology. 2003:38 Suppl 1():S54-68
24. Vorobioff J, Groszmann RJ, Picabea E, Gamen M, Villavicencio R, Bordato J, Morel I, Audano M, Tanno H, Lerner E, Passamonti M. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology. 1996 Sep:111(3):701-9
25. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology. 1981 Apr:80(4):800-9
26. Garbuzenko DV. Contemporary concepts of prevention and management of gastroesophageal variceal bleeding in liver cirrhosis patients. World journal of hepatology. 2024 Feb 27:16(2):126-134. doi: 10.4254/wjh.v16.i2.126.
27. Rehman H, Rehman ST, Zulfiqar S, Awan S, Abid S. Real-world comparison of terlipressin vs. octreotide as an adjuvant treatment in the management of variceal bleeding. Scientific

reports. 2024 Mar 20:14(1):6692. doi: 10.1038/s41598-024-56873-x
28. Quraishi MN, Khan F, Tripathi D. How we manage variceal hemorrhage in cirrhotic patients. Key practical messages from the British Guidelines. Polskie Archiwum Medycyny Wewnetrznej. 2016:126(3):174-84. doi: 10.20452/pamw.3319.
29. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F, Soares-Weiser K, Mendez-Sanchez N, Gluud C, Uribe M. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review. Alimentary pharmacology & therapeutics. 2011 Sep:34(5):509-18. doi: 10.1111/j.1365-2036.2011.04746.x.
30. Escorsell A, Bañares R, García-Pagán JC, Gilabert R, Moitinho E, Piqueras B, Bru C, Echenagusia A, Granados A, Bosch J. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. Hepatology (Baltimore, Md.). 2002 Feb:35(2):385-92
31. Pedersen JS, Bendtsen F, Møller S. Management of cirrhotic ascites. Therapeutic advances in chronic disease. 2015 May:6(3):124-37. doi: 10.1177/2040622315580069